- 100% Disease Control in 2L NSCLC Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
- Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage NSCLC
- Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors
- Botensilimab/Balstilimab Combination Delivers Durable Responses Across Multiple Sarcoma Subtypes
- Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study presented
- Datopotamab deruxtecan significantly extended PFS vs. chemo in patients with HR-positive, HER2-low/neg breast cancer in TROPION-Breast01 Phase III trial
- Datopotamab deruxtecan improved PFS vs. chemotherapy in patients with previously treated NSCLC in TROPION-Lung01 Phase III trial
- Datopotamab deruxtecan + Imfinzi demonstrated robust and durable tumour responses in 1L treatment of patients with mTNBC in BEGONIA Phase Ib/II trial
- Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial
- Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone
- First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with NMIBC with Select FGFR Alterations
- Gilead And Kite Oncology Present Important New Data Across Multiple Difficult-To-Treat Cancers
- HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers
- Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
- Imfinzi plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and GEJ cancers versus chemo alone
- Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
- KEYTRUDA + Chemo Showed Statistically Significant Improvement in pCR Rate as Neoadjuvant Therapy vs Chemo in High-Risk, Early-Stage ER+/HER2- Breast Cancer
- KEYTRUDA + Chemo Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemo in Resectable Stage II, IIIA or IIIB NSCLC
- KEYTRUDA + Concurrent chemoRT Significantly Improved PFS vs Concurrent chemoRT Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
- KEYTRUDA + Padcev Reduced Risk of Death by More Than Half vs Chemo in Patients With 1L Locally Advanced or Metastatic Urothelial Cancer
- KEYTRUDA + Trastuzumab and Chemo Significantly Improved PFS Versus Trastuzumab & Chemo in 1L HER2+ve Advanced GEJ Adenocarcinoma
- Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
- Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)’s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
- Libtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging EFS in Patients with Resectable CSCC
- Neoadjuvant Opdivo + Chemo Provides Benefits for Patients with Resectable NSCLC Across PD-L1 expression levels with 3-Year follow Up in CheckMate-816 Trial
- New And Updated Botensilimab Data In Colorectal, Pancreatic, Lung, Melanoma, And Sarcoma presented
- New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) + Chemo Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
- New Lumakras (Sotorasib) + Vectibix (Panitumumab) Data In Patients With KRAS G12C-Mutated mCRC presented
- New Tarlatamab Data In SCLC presented
- Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
- Opdivo + Cisplatin-Based Chemo Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
- Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide & Updated Positive Interim Data from 2nd gen ARV-766 in mCRPC
- Perioperative Regimen of Neoadjuvant Opdivo & Chemo Followed by Adjuvant Opdivo Shows Significant Improvement in EFS for Patients with Resectable NSCLC in Phase 3 CheckMate -77T Trial
- Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
- Phase 3 MARIPOSA-2 Study Shows RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib
- Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and EFS for Tislelizumab + Chemo in Patients with Resectable NSCLC
- Pluvicto™ Shows Clinically Meaningful And Highly Statistically Significant rPFS Benefit In Patients With PSMA-Positive mCRPC In The Pre-Taxane Setting
- Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
- Results Evaluating the Combination of Adagrasib and Pembrolizumab in 1L NSCLC presented
- Results from Phase 2 THOR-2 Study Show Improved Rates of RFS in Patients with High-Risk NMIBC with Select FGFR Alterations Treated with BALVERSA® (erdafitinib) Vs Chemo
- Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive NSCLC and RET-Mutant Medullary Thyroid Cancer Both Published in The NEJM and Presented
- Tagrisso plus chemo reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain mets at baseline
- TAR-200 Intravesical Delivery System Results Show 77 Percent CRR in Patients with BCG Unresponsive, High-Risk NMIBC
- Tislelizumab + chemo Significantly Improved OS at Final Analysis in 1L Advanced Gastric or GEJ
- TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged OS in Patients with Recurrent/Metastatic Cervical Cancer vs Chemo in Phase 3 innovaTV 301 Trial
- WELIREG® (belzutifan) Significantly Improved PFS and ORR Versus Everolimus in Certain Previously Treated Patients With Advanced RCC
Menu
